Evidence map›Paper›PMID 41415569›Full record

ArticleFrontiers in pharmacology2025

Novel drug candidates targeting

Rafael Martins de Oliveira, Natália Carine Lima Dos Santos, Marcos Paulo Oliveira Almeida, Joed Pires De Lima Júnior, Guilherme De Souza, Matheus Carvalho Barbosa, Guilherme Vieira Faria, Marina Paschoalino, Rosiane Nascimento Alves, Angelica Oliveira Gomes and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Investigation of the Anti-Pathogens (Basel, Switzerland) · 2026
    Article
  2. Quercetin ReducesInternational journal of molecular sciences · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rafael Martins de OliveiraLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Natália Carine Lima Dos SantosLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Marcos Paulo Oliveira AlmeidaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Joed Pires De Lima JúniorLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Guilherme De SouzaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Matheus Carvalho BarbosaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Guilherme Vieira FariaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Marina PaschoalinoLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Rosiane Nascimento AlvesDepartment of Agricultural and Natural Science, Universidade do Estado de Minas Gerais, Ituiutaba, Minas Gerais, Brazil.
Angelica Oliveira GomesLaboratory of Cell Interactions, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, Uberaba, Minas Gerais, Brazil.
Juliana Quero ReimãoLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (Lab. PARASITTOS), Department of Morphology and Basic Pathology, Faculdade de Medicina de Jundiaí, Jundiaí, São Paulo, Brazil.
Bellisa Freitas BarbosaLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Samuel Cota TeixeiraLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Eloisa Amália Vieira FerroLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Toxoplasmosis is a disease caused by the protozoan Methods: In this study, we evaluated three MMV Pathogen Box compounds-MMV675968, MMV022478, and MMV021013-for their ability to control Results: Nontoxic concentrations of all the three compounds irreversibly inhibited parasite proliferation and interfered with early stages of the lytic cycle, including adhesion and infection. Moreover, treated Conclusion: Taken together, our findings support the potential of MMV675968, MMV022478, and MMV021013 as promising drug candidates for the treatment of congenital toxoplasmosis. MMV021013 stands out as the most promising compound, combining high predicted gastrointestinal (GI) absorption and blood-brain barrier (BBB) permeability, with no predicted mutagenic, tumorigenic, irritant, or reproductive effects.

Indexed as

congenital toxoplasmosisdrug repurposingMedicines for Malaria VenturePathogen BoxToxoplasma gondii

Identifiers

PMID41415569
PMCPMC12708611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.